China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne
HANGZHOU and SHAOXING, China, Aug. 8, 2021 /PRNewswire/ — Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment…
